17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

Inclusion Criteria: * Negative pregnancy test * Fertile patients must use effective contraception prior to and during study treatment * Must have normal organ and marrow function * Not a candidate for stem cell transplantation * ECOG 0-2 OR Karnofsky 60-100% * Bilirubin normal * Creatinine normal * Histologically or cytologically confirmed relapsed or refractory mantle cell lymphoma, anaplastic large cell lymphoma (CD30-positive disease), or classical Hodgkin's lymphoma * Recovered from prior biologic therapy or autologous stem cell transplantation * Prior antibody therapy within the past 3 months allowed * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * More than 4 weeks since prior radiotherapy (12 weeks for radioimmunotherapy) and recovered * Recovered from prior investigational drugs * Recovered from prior surgery * More than 4 weeks since other prior anticancer therapy * Concurrent low-molecular weight heparin is allowed * Measurable disease, defined as \>= 1 unidimensionally measurable lesion \>= 20 mm * Absolute neutrophil count \>= 1,500/mm3 * Received \>= 1, but =\< 3, prior treatment regimens for lymphoma (salvage therapy followed immediately by stem cell transplantation is considered 1 regimen). Single-agent monoclonal antibody therapy, cytokine therapy, or involved field radiotherapy are not considered prior treatment regimens. All prior treatments and prior antibody therapy within the past 3 months are recorded. * Platelet count \>= 75,000/mm3 * AST and ALT =\< 1.5 times upper limit of normal * Understand and provide signed informed consent. Exclusion Criteria: * No cardiac arrhythmia or uncontrolled dysrhythmia * No history of myocardial infarction within the past year * No New York Heart Association class III or IV heart failure * No other significant cardiac disease * No paroxysmal nocturnal dyspnea * No oxygen requirement * No AIDS * No history cardiac toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubcin hydrochloride, mitoxantrone, bleomycin, or carmustine) * No pulmonary lymphoma * No known CNS lymphoma * QTc \>/= 450 msec for men * QTc \>/= 470 msec for women * LVEF \</= 40% by MUGA * No symptomatic congestive heart failure * No unstable angina pectoris * No symptomatic pulmonary disease requiring medication * No significant pulmonary disease including chronic obstructive or restrictive pulmonary disease * No dyspnea on or off exertion * No history of pulmonary toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubcin hydrochloride, mitoxantrone, bleomycin, or carmustine) * Not pregnant or nursing * No other uncontrolled illness * No other active\* malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix * No prior allogeneic stem cell transplantation * No history of allergic reaction to eggs * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No prior chest radiation or prior radiation that potentially included the heart in the field (e.g.,mantle). * No concurrent medications that prolong or may prolong QTc * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent investigational agents * No other concurrent anticancer therapy * No prior cardiac symptoms \>= grade 2 * No sufficiently compromised pulmonary status (i.e., DLCO =\< 80%) * No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or ventricular fibrillation \>= 3 beats in a row) * No prior pulmonary symptoms \>= grade 2 * HIV negative * No active ischemic heart disease within 12 months. * No congenital long QT syndrome. * No left bundle branch block.